Morphocell Technologies completes US$50 Million Series A financing

Dec 2

Morphocell Technologies Inc., a biotechnology company pioneering next-generation tissue therapeutics for organ replacement, recently announced the completion of its US$50 million Series A financing following a US$10 million add-on led by Investissement Québec, the province’s leading economic development corporation, and CDP Venture Capital, part of Italy’s Cassa Depositi e Prestiti (CDP) group.

Morphocell Technologies presented at the OBIO® Investment Summit.

Arsheen Kaur

Morphocell Technologies completes US$50 Million Series A financing

Vasomune Therapeutics and AnGes expand the scope of the co-development agreement to target﻿ additional indications

Vasomune Therapeutics and AnGes expand the scope of the co-development agreement to target additional indications